CAJ | 학술논문

欧洲和亚洲等多个地区和国家的荨麻疹指南中均提到荨麻疹的4层次治疗。荨麻疹的第1层次治疗为非镇静的H1受体拮抗剂；第2层次治疗使用非镇静的H1受体拮抗剂为常规剂量的2～4倍；第3层次治疗为抗组胺药物联合白三烯受体拮抗剂或短时间的系统使用糖皮质激素；第4层次治疗是在第1层次治疗的基础上联合环孢素、奥马株单抗或氨苯砜等药物。临床医师应根据个体情况，选择合适的治疗方案。
구주화아주등다개지구화국가적담마진지남중균제도담마진적4층차치료。담마진적제1층차치료위비진정적H1수체길항제；제2층차치료사용비진정적H1수체길항제위상규제량적2～4배；제3층차치료위항조알약물연합백삼희수체길항제혹단시간적계통사용당피질격소；제4층차치료시재제1층차치료적기출상연합배포소、오마주단항혹안분풍등약물。림상의사응근거개체정황，선택합괄적치료방안。
The urticarial guidelines in multiple regions and countries of Europe and Asia referred a four-level medicine treatments on urticaria.The ifrst-level medicine treatment of urticaria is new generation, nonsedating H1-antihistamines. The second-level medicine treatment is increasing the dosage of nonsedating H1-antihistamines up two to four-fold. The third-level medicine treatment is antihistamines and leukotriene antagonist or short courses of systemic steroids. The fourth-level medicine treatment is to add the following drugs including cyclosporine, omalizumab ordapsone based on the ifrst-level medicine treatment. Clinicians should select appropriate treatments based on individual circumstances.